HOME >> MEDICINE >> NEWS
Early promise of alternative hormone treatment

A fast-track study in this week's issue of THE LANCET suggests that the drug anastrozole could be an effective option for the treatment of postmenopausal women with hormone-sensitive early breast cancer.

Tamoxifen therapy for five years after surgery is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, its use is associated with several side-effects including endometrial cancer and blood-clotting disorders. The ATAC investigators led by Michael Baum from University College London, UK, and colleagues was an international study which aimed to compare the safety and efficacy of tamoxifen with anastrozole alone and the combination of both drugs for 5 years.

9366 postmenopausal women from 21 countries who had undergone breast-cancer surgery were studied; 3125 were randomly assigned anastrozole, 3116 tamoxifen, and 3125 combination therapy. The average follow-up was just under three years (33 months).

Three-year disease-free survival was 2% greater among women given anastrozole (89.4%) compared with those given tamoxifen (87.4%). Combination therapy with both drugs showed no additional benefit compared with women given tamoxifen. Anastrozole was better tolerated than tamoxifen with respect to endometrial cancer, vaginal bleeding and discharge, stroke, venous thromboembolic events, and hot flushes. Tamoxifen was significantly better tolerated than anastrozole with respect to musculoskeletal disorders and bone fractures.

Michael Baum comments: "Evidence from this first analysis of the ATAC trial is encouraging. An important consideration at this time is how to treat newly diagnosed patients. An overall assessment of the benefits versus harm, based on current data, supports the use of anastrozole for the adjuvant treatment of early breast cancer in postmenopausal women, meaning that there is now a choice of adjuvant endocrine therapy for postmenopausal women with hormone-responsive tumour
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-4244949
Lancet
20-Jun-2002


Page: 1 2

Related medicine news :

1. Early onset of puberty the EU gets serious
2. Early HIV screening prolongs life and is affordable, Stanford study shows
3. Early supported discharge services can reduce long term dependency for stroke patients
4. Early surgical treatment not always necessary for patients with brain haemorrhage
5. Early seizures after epilepsy surgery predict more seizures
6. Early learning leaves lasting changes in brain, Stanford owl study shows
7. Early detection reduces threat of foot injury in college basketball players
8. Early results shed light on lung cancer screening advance
9. Early disclosure: Post-operative radiotherapy improves progression-free survival in prostate cancer
10. Early reports of thrombosis after insertion of drug-eluting stents
11. Early behavior problems linked with wheezing later in childhood

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... ARLINGTON, Va. (PRWEB) , ... February 19, 2019 , ... ... new member of the Board of Directors. , Claudia is the CEO and Co-Founder ... impact on the health and wellness of people and the planet. She is a ...
(Date:2/19/2019)... (PRWEB) , ... February 19, 2019 , ... ... years of medical experience to The Oncology Institute of Hope and Innovation. , ... he graduated magna cum laude. He received his medical degree from the University ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... their newest release of their enrollment kit solution, called ONEkit™ 2.0. This new ... their new and existing customers. ONEkit is integrated with O’Neil’s Omni-channel system, allowing ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... survivor and well-respected advocate for patient engagement, will deliver the luncheon keynote ... brings critical awareness of participatory medicine and empowering partnerships between patients and their ...
(Date:2/19/2019)... ... February 18, 2019 , ... U.S. Patent No. ... 10,195,147 titled, “Dry powder aspirin compositions with magnesium stearate,” protect the ASPRIHALE™ formulation ... three previously granted utility patents, two issued by the USPTO and one issued ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... Fla. (PRWEB) , ... February 19, 2019 , ... ... knowledge and professional experiences with students from kindergarten through 6th grade at the ... live specimens, life cycle, mosquito surveillance and control with an emphasis on what ...
(Date:2/19/2019)... ... February 19, 2019 , ... TopConsumerReviews.com recently gave its best-in-class 5 star ... prevent Lice. , Lice outbreaks are surprisingly common, especially in schools and other environments ... lice is not a sign of uncleanliness; in fact, lice prefer to live on ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... Senior Vice President. Kunney, based in Atlanta, is an experienced IT leader ... that effectively integrate within the clinical setting. He works with hospitals, health ...
Breaking Medicine Technology:
Cached News: